Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 14Lymphoma, Non-Hodgkin 10Breast Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Solid Tumors 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Melanoma 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Arthritis, Rheumatoid 4Ovarian Neoplasms 3Lymphoma, Follicular 3Leukemia 3Hematologic Neoplasms 3Cytokine Release Syndrome 3Colorectal Neoplasms 3Burkitt Lymphoma 3Urinary Bladder Neoplasms 2Respiratory Distress Syndrome 2Pancreatic Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Fallopian Tube Neoplasms 2Craniopharyngioma 2Carcinoma, Hepatocellular 2

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Interleukin-2 9Melphalan 8CTLA-4 Antigen 8sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7tebentafusp 6Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Bevacizumab 5aldesleukin 4aflibercept 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Blood Specimen Collection 4Biopsy 4trametinib 3sotrastaurin 3relatlimab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uveal Melanoma × tocilizumab × Clear all
NCT04551352 2022-10-03

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Hoffmann-La Roche

Phase 1 Completed
20 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡